Business Context and Reporting Period
This Form 8-K Current Report was filed by Rexahn Pharmaceuticals, Inc. on September 14, 2016. The filing discloses the entry into a Material Definitive Agreement regarding a registered direct offering of equity securities. Note: The request metadata referenced "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $6.0 million from the sale of 24,000,000 shares of common stock and warrants exercisable for up to 18,000,000 shares.
- Offering Price: $0.25 per unit (one share of common stock plus a warrant to purchase 0.75 of a share).
- Net Proceeds: Approximately $5.5 million after deducting placement agent fees, expenses, and estimated offering costs.
- Placement Agent Fees: 6% of gross proceeds paid to Rodman & Renshaw (a unit of H.C. Wainwright & Co., LLC), plus $30,000 for expenses.
- Warrant Terms (Investors): Exercise price of $0.30 per share; exercisable beginning six months after issuance; expire five years from the initial exercise date.
- Warrant Terms (Agent): 1,440,000 warrants granted to the placement agent with an exercise price of $0.3125 per share; expire September 14, 2021.
Material Changes
The filing reports a significant capital raise event. The company entered into a Securities Purchase Agreement to sell equity and warrants to institutional investors. This transaction represents a dilution of existing shareholders through the issuance of 24 million new shares and warrants for an additional 18 million shares. The filing does not provide comparative financial data (revenue, profit, or cash flow) for prior periods as this is a transactional report rather than a periodic financial statement.
Outlook, Risks, and Contingencies
- Closing Date: The offering is expected to close on or about September 19, 2016, subject to customary closing conditions.
- Registration: Securities are being issued pursuant to a prospectus supplement filed under an effective shelf registration statement (Form S-3).
- Unregistered Sales: Warrants granted to the placement agent are issued in reliance on the Section 4(a)(2) exemption from registration.
- Adjustments: Warrant share counts and exercise prices are adjustable for stock splits, dividends, or recapitalization transactions.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected September 19, 2016) and confirm receipt of net proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions on the use of proceeds.
- Monitor the impact of the 24 million new shares and 18 million warrant shares on existing shareholder dilution.
- Confirm the filing of the prospectus supplement referenced in the text to review the final terms of the offering.